Degarelix (acetate) – 10 mg

Brand:
Cayman
CAS:
934016-19-0
Storage:
-20
UN-No:
Non-Hazardous - /

Degarelix is a synthetic gonadotropin-releasing hormone receptor (GNRHR) antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor).{39553} It inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines following a 72-hour incubation at a concentration of 10 μM via caspase activation and induction of apoptosis.{39554} In vivo, degarelix (2 mg/kg) decreases plasma testosterone levels in rats to castrate levels for the first 49 days post administration.{39553} It decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats when administered at a dose of 1 mg/kg per month.{39555} Formulations containing degarelix have been used in the treatment of advanced prostate cancer.  

 

Available on backorder

SKU: 24069 - 10 mg Category:

Description

A synthetic GNRHR antagonist (IC50 = 3 nM in HEK293 cells expressing the human receptor); inhibits the growth of WPMY-1, WPE1-NA22, BPH-1, and LNCaP prostate cell lines via caspase activation and induction of apoptosis (10 μM); decreases plasma testosterone levels in rats to castrate levels for the first 49 days post treatment (2 mg/kg); decreases tumor volume of Dunning R3327H prostate tumor flank implants in rats (1 mg/kg per month),


Formal name: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-4-[[[(4S)-hexahydro-2,6-dioxo-4-pyrimidinyl]carbonyl]amino]-L-phenylalanyl-4-[(aminocarbonyl)amino]-D-phenylalanyl-L-leucyl-N6-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, monoacetate

Synonyms:  FE 200486

Molecular weight: 1,692.30

CAS: 934016-19-0

Purity: ≥98%

Formulation: A crystalline solid


Product Type|Biochemicals|Receptor Pharmacology|Antagonists||Product Type|Biochemicals|Small Molecule Activators|Caspases||Research Area|Cancer|Cell Death|Apoptosis||Research Area|Endocrinology & Metabolism|Hormones & Receptors